De Felice Francesca, Guerrero Urbano Teresa
Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.
Department of Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Oral Oncol. 2017 Apr;67:119-123. doi: 10.1016/j.oraloncology.2017.02.020. Epub 2017 Feb 27.
Over the last few years a number of new different compounds have been developed. They include phosphatidylinositol 3-kinase (PI3-K) inhibitors. Deregulation within the PI3-K pathway is common in head neck squamous cell carcinoma (HNSCC) and it represents a growing area of research. PI3-K inhibitors, including BKM120, PX-866 and BYL719, are being tested in several phase I and phase II studies in patients with locally advanced, recurrent or metastatic disease. This review provides an update of published clinical trials and highlights the challenges of PI3-K inhibitors in HNSCC.
在过去几年中，已经开发出了许多新型不同化合物。其中包括磷脂酰肌醇3激酶（PI3-K）抑制剂。PI3-K信号通路失调在头颈部鳞状细胞癌（HNSCC）中很常见，并且它是一个不断发展的研究领域。包括BKM120、PX-866和BYL719在内的PI3-K抑制剂正在针对局部晚期、复发或转移性疾病患者进行多项I期和II期研究测试。本综述提供了已发表临床试验的最新情况，并强调了PI3-K抑制剂在HNSCC治疗中的挑战。
